Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amanda Moran

Physical Medicine & Rehabilitation Norfolk, VA Doctor of Osteopathy

NPI 1992231039 CMS profile 7215774

6275 E Virginia Beach Blvd Ste 303, Norfolk, VA 23502

Open in the dashboard

General payments

$9,133

418 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Moran of Norfolk, VA is reported in the CMS Open Payments database as having received $9,133 across 418 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,469 67
2024 General $1,888 98
2023 General $1,571 102
2022 General $2,872 127
2021 General $612 16
2020 General $164 3
2019 General $556 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Moran
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Amanda Moran were reported at $1,469. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Amanda Moran Physical Medicine & Rehabilitation median Middle half National median
2019 $556 $133 $45–$390 $163
2020 $164 $88 $29–$272 $114
2021 $612 $116 $33–$360 $132
2022 $2,872 $123 $40–$378 $149
2023 $1,571 $131 $43–$396 $160
2024 $1,888 $141 $45–$409 $164
2025 $1,469 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,996 111 payments
  2. Lundbeck LLC $1,201 61 payments
  3. Collegium Pharmaceutical, Inc. $827 39 payments
  4. Teva Pharmaceuticals USA, Inc. $660 10 payments
  5. Pfizer Inc. $545 40 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $449 23 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $348 22 payments
  8. Janssen Pharmaceuticals, Inc $336 4 payments
  9. Allergan Inc. $301 6 payments
  10. Amgen Inc. $284 9 payments
  11. Other $2,185 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,133 418 payments
Products named General payments · program years 2019–2025
  1. VYEPTI $1,015 49 payments
  2. UBRELVY $972 61 payments
  3. QULIPTA $940 57 payments
  4. NURTEC ODT Pain $545 40 payments
  5. XTAMPZA $530 24 payments
  6. BOTOX $497 24 payments
  7. AJOVY $451 6 payments
  8. NURTEC ODT Primary Care $449 23 payments
  9. ZAVZPRET $441 33 payments
  10. BELBUCA $297 15 payments
  11. Other $4,705 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,268

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$271,309

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

25.2%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 42 $81,582
Nurtec Odt Rimegepant Sulfate Brand 28 $52,414
Fentanyl Generic 121 $27,782
Ubrelvy Ubrogepant Brand 15 $21,421
Xtampza Er Oxycodone Myristate Brand 18 $19,746
Oxycodone Hcl Generic 405 $14,542
Hydromorphone Hcl Hydromorphone Hcl/Pf Brand 60 $9,437
Hydromorphone Hcl Generic 131 $5,822
Morphine Sulfate Er Morphine Sulfate Brand 123 $5,573
Movantik Naloxegol Oxalate Brand 12 $5,558

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$197,270

Of which drugs: $79,918

Medicare patients

380

Average age 66

Services billed

26,866

253 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Depression 45%
Diabetes 31%
COPD 24%
Chronic kidney disease 21%
Ischemic heart disease 19%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Capsaicin 8% patch, per square centimeter J7336 Office 11 19,040 $49,632
Injection, onabotulinumtoxina, 1 unit J0585 Office 16 6,355 $30,262
Injection, ketorolac tromethamine, per 15 mg J1885 Office 13 21 $13
Injection, methylprednisolone acetate, 1 mg J1010 Office 21 45 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
  • Lundbeck LLC $512
$512 — —
BOTOX
  • AbbVie, Inc. $192
$192 — 6,355
UBRELVY
  • AbbVie, Inc. $177
$177 15 —
QULIPTA
  • AbbVie, Inc. $176
$176 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $170
$170 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

418 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record